Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) announced that as of Feb 19, 2026 all prefunded warrants from its Oct 2025 private placement were fully exercised, leaving approximately 972,000 shares of common stock outstanding.

The company reports about 1.5 million cash-exercisable warrants remain, each with a cash exercise price of $7.00 or greater, and reminds investors that Schedule 13G filings may show pre-split share counts after the 1-for-4 reverse split on Jan 29, 2026.

Positive

• Prefunded warrants fully exercised, simplifying capital structure
• Common shares outstanding reduced to approximately 972,000
• Remaining cash-exercisable warrants tied to exercise prices ≥ $7.00

Negative

• Approximately 1.5 million cash-exercisable warrants remain, potential dilution if exercised
• Schedule 13G filings may misstate post-split ownership due to pre-split reporting

News Market Reaction – BJDX

+1.51% 10.7x vol

12 alerts

+1.51% News Effect

+14.3% Peak Tracked

-12.9% Trough Tracked

+$21K Valuation Impact

$1.41M Market Cap

10.7x Rel. Volume

On the day this news was published, BJDX gained 1.51%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.3% during that session. Argus tracked a trough of -12.9% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $21K to the company's valuation, bringing the market cap to $1.41M at that time. Trading volume was exceptionally heavy at 10.7x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement clarified Bluejay’s capital structure by confirming that all prefunded warrants fr...

Analysis

This announcement clarified Bluejay’s capital structure by confirming that all prefunded warrants from the October 2025 private placement were fully exercised, leaving roughly 972,000 common shares and about 1.5 million cash exercisable warrants with strikes of at least $7.00. It also highlighted confusion from Schedule 13G filings that did not reflect the 1-for-4 reverse split. Investors may track further warrant exercises, use of the S-3 resale registration for 6,930,000 shares, and progress toward FDA authorization for the Symphony IL-6 sepsis test.

Key Figures

Shares outstanding: 972,000 shares Warrants outstanding: 1.5 million shares Warrant exercise price: $7.00 per share +2 more

5 metrics

Shares outstanding 972,000 shares Common stock outstanding after full exercise of prefunded warrants

Warrants outstanding 1.5 million shares Cash exercisable warrants for approximately 1.5M shares

Warrant exercise price $7.00 per share Cash exercise price for all outstanding cash exercisable warrants

Reverse split ratio 1-for-4 Reverse stock split effective January 29, 2026, referenced in the article

Test turnaround time 20 minutes Symphony IL-6 sepsis test sample-to-result time

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Clinical/manufacturing update	Positive	+0.8%	Reported 545 SYMON II enrollments and manufacturing readiness progress toward 750 target.
Jan 27	Reverse stock split	Negative	-3.9%	Announced 1-for-4 reverse split reducing shares outstanding and adjusting warrants.
Dec 29	Antibody production	Positive	-3.0%	Completed commercial-scale IL-6 antibody production meeting internal performance criteria.
Nov 10	Corporate update	Neutral	+0.0%	Provided Q3 2025 update on SYMON-II progress, timelines, and financing activities.
Oct 10	Private placement	Negative	-2.7%	Closed $4.5M private placement with shares or prefunded and Series F warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across recent events, BJDX has mostly traded in line with news tone, with 4 aligned moves and 1 divergence, including a negative reaction to positive antibody production news.

Recent Company History

Over the past few months, Bluejay announced a 1-for-4 reverse split effective Jan 29, 2026, completion of commercial-scale IL-6 antibody production, and enrollment of 545 patients toward a 750-patient SYMON II target. Financing steps included an October $4.5M private placement. Market reactions were modest, with mostly small percentage moves. Today’s update that all prefunded warrants from the October 2025 private placement have been exercised fits into this broader capital-structure and clinical-execution narrative.

Key Terms

prefunded warrants, reverse stock split, schedule 13g, beneficial ownership, +4 more

8 terms

prefunded warrants financial

"all of the prefunded warrants issued by the Company in its October 2025 private placement"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

reverse stock split financial

"the 1-for-4 reverse stock split that occurred on January 29, 2026"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

schedule 13g regulatory

"several recent Schedule 13G filings made by investors do not reflect"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial ownership regulatory

"current beneficial ownership share amounts may therefore be significantly less"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

View in glossary

u.s. food and drug administration regulatory

"we will need to receive regulatory authorization from the U.S. Food and Drug Administration"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

sepsis medical

"a cost-effective, rapid, near-patient testing system for sepsis triage"

Sepsis is a dangerous medical condition in which an infection triggers the body's defenses to damage its own tissues and organs, often leading to organ failure and emergency hospital care. For investors it matters because sepsis drives demand for diagnostics, antibiotics, intensive-care treatments and hospital resources, affects healthcare costs and insurer payouts, and can influence the commercial prospects and valuation of companies developing related tests, drugs and devices.

il-6 medical

"Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed"

Interleukin-6 (IL-6) is a small signaling protein the body releases as an alarm during infection, injury, or chronic inflammation; think of it as a smoke detector that calls immune cells to action. It matters to investors because IL-6 levels can serve as a biomarker for disease severity and a target for therapies—drugs that block or modulate IL-6 can change treatment outcomes, regulatory decisions, and commercial prospects in healthcare markets.

near-patient testing medical

"a cost-effective, rapid, near-patient testing system for sepsis triage"

Near-patient testing means medical tests performed close to where a patient is being seen — for example in a clinic, pharmacy, ambulance, or at home — instead of being sent to a distant laboratory. For investors, it matters because these faster, simpler tests can speed diagnosis and treatment, broaden access, lower ongoing costs, and create new sales and recurring-revenue opportunities much like a compact kitchen appliance that brings restaurant capabilities into the home.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share.

The Company notes that several recent Schedule 13G filings made by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, and investors reading such filings should be aware that current beneficial ownership share amounts may therefore be significantly less than the number of shares reflected in such reports given that these reports show holdings and total shares outstanding on a pre-split basis, notwithstanding that such reports were filed after consummation of the 1-for-4 reverse stock split.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and in Part II, Item 1A, “Risk Factors” in the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 13, 2025, August 7, 2025 and November 7, 2025, respectively. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com

FAQ

How many common shares does Bluejay Diagnostics (BJDX) have outstanding after the warrant exercises?

Bluejay now has approximately 972,000 common shares outstanding. According to the company, this follows full exercise of all prefunded warrants as of Feb 19, 2026.

How many cash-exercisable warrants does BJDX have and at what price can they be exercised?

Bluejay has cash-exercisable warrants for about 1.5 million shares, each with an exercise price of $7.00 or greater. According to the company, these remain outstanding following the prefunded warrant exercises.

What does the 1-for-4 reverse stock split mean for BJDX shareholders and filings?

The 1-for-4 reverse split, effective Jan 29, 2026, reduced outstanding share counts by four-fold. According to the company, some Schedule 13G filings still show pre-split figures and may overstate current holdings.

Will the exercised prefunded warrants affect Bluejay Diagnostics' capital structure?

Yes, exercising prefunded warrants reduced the number of outstanding warrant classes and set common shares at ~972,000. According to the company, this simplifies the outstanding prefunded warrant position.

How should investors interpret Schedule 13G reports filed after Jan 29, 2026 for BJDX?

Investors should adjust reported holdings to reflect the Jan 29, 2026 reverse split, as some Schedule 13G filings still show pre-split shares. According to the company, reported numbers may therefore be significantly higher than current shares.